Claritev (CTEV) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
16 Dec, 2025Executive summary
Achieved a second consecutive quarter of beat-and-raise performance, with Q3 2025 revenue up 6.7% year-over-year to $246 million, driven by core business growth and major client renewals.
Net loss narrowed to $69.8 million from $391.5 million in Q3 2024, with no goodwill or intangible asset impairments recorded in 2025.
Expanded into new market verticals, including international markets and government, with first revenue from the MENA region and new partnerships.
Completed migration to Oracle Cloud Infrastructure, improving scalability and performance.
Rebrand efforts increased brand engagement, with website visits up over 100%.
Financial highlights
Q3 2025 revenue was $246 million, up 6.7% year-over-year; adjusted EBITDA was $155.1 million, up 9.5% with a margin of 63.1%.
Adjusted EPS for Q3 2025 was $1.48; net loss per share improved to $(4.23) from $(24.25) in Q3 2024.
Unlevered free cash flow was $113 million, while levered free cash flow was a use of $16.3 million in Q3.
Cash and cash equivalents at quarter-end were $39.2 million, with $273.6 million available under the revolving credit facility.
Best absolute revenue dollar performance in the last 12 quarters.
Outlook and guidance
Raised full-year 2025 revenue growth guidance to 2.8%–3.2% and adjusted EBITDA margin guidance to 62.5%–63.0%.
Capital expenditures expected at $165–$175 million for FY 2025.
Free cash flow guidance remains $(20) million to $20 million.
Management expects sufficient liquidity for the next twelve months, supported by internal cash generation and borrowing capacity.
Expecting $60 million of incremental ACV to largely convert to revenue in 2026 and beyond.
Latest events from Claritev
- Record bookings, robust AI-driven growth, and disciplined investment fuel expansion.CTEV
Status update6 Mar 2026 - Revenue and EBITDA grew, losses narrowed, and 2026 outlook includes buybacks and expansion.CTEV
Q4 202523 Feb 2026 - Q2 2024 net loss was $576.7M on $233.5M revenue, driven by a $553.7M impairment.CTEV
Q2 20242 Feb 2026 - Q3 2024 net loss surged on a $361.6M impairment as revenue fell 5.1% year-over-year.CTEV
Q3 202416 Jan 2026 - Transformation, tech investment, and data-driven strategy fuel growth and innovation in healthcare.CTEV
44th Annual J.P. Morgan Healthcare Conference15 Jan 2026 - 2024 revenue declined 3.2% and net loss spiked on impairment as transformation accelerates.CTEV
Q4 202423 Dec 2025 - Healthcare cost management firm files to offer up to $400M in securities for growth and operations.CTEV
Registration Filing16 Dec 2025 - Renewed top clients, expanded pipeline, and strong growth in analytics drive positive outlook.CTEV
Piper Sandler 37th Annual Healthcare Conference4 Dec 2025 - Six new market segments and Oracle partnership drive growth and international expansion.CTEV
BofA Securities Leveraged Finance Conference 20253 Dec 2025